Helen Knight, director of medicines evaluation at Nice, said: “The appraisal committee considered that exa-cel could represent a potential cure for some people with sickle cell disease, freeing people from the burden of VOCs (vaso-occlusive crises) as well as addressing Nice’s aim of reducing health inequalities associated with the condition.
Birdily
Related